Iran vs Middle East, North Africa, Afghanistan & Pakistan (excluding high income): Immunization, Hib3
Immunization, Hib3 over time
- Iran
- Middle East, North Africa, Afghanistan & Pakistan (excluding high income)
How they compare
Iran currently reports 98.0% against 83.7% in Middle East, North Africa, Afghanistan & Pakistan (excluding high income), a difference of 14.3%.
That makes Iran's figure about 1.2 times Middle East, North Africa, Afghanistan & Pakistan (excluding high income)'s.
Across all 10 years both countries report, Iran has been ahead every year.
Iran ranks 20th and Middle East, North Africa, Afghanistan & Pakistan (excluding high income) ranks 20th of 191 countries.
Iran has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Iran | Middle East, North Africa, Afghanistan & Pakistan (excluding high income) | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 98.8% | 82.0% | 16.8% | Iran |
| 2020s | 98.6% | 82.6% | 16.0% | Iran |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher immunization, hib3, Iran or Middle East, North Africa, Afghanistan & Pakistan (excluding high income)?
- Iran, at 98.0% against 83.7% in Middle East, North Africa, Afghanistan & Pakistan (excluding high income) as of 2024.
- What is the difference in immunization, hib3 between Iran and Middle East, North Africa, Afghanistan & Pakistan (excluding high income)?
- 14.3%, with Iran ahead.
- How many years of comparable data are there for Iran and Middle East, North Africa, Afghanistan & Pakistan (excluding high income)?
- 10 years are reported by both, from 2015 to 2024.
- How do Iran and Middle East, North Africa, Afghanistan & Pakistan (excluding high income) rank globally for immunization, hib3?
- Iran ranks 20th and Middle East, North Africa, Afghanistan & Pakistan (excluding high income) ranks 20th of 191 countries.
- Where does this data come from?
- WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/), published as Immunization, Hib3 (% of children ages 12-23 months). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Child immunization, Hib3, measures the percentage of children ages 12-23 months who received Hib3 vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against Hib3 after receiving three doses of Haemophilus influenzae type b vaccine.